歌禮製藥(01672.HK)ASC40獲批開展痤瘡治療二期臨床試驗
歌禮製藥(01672.HK)公布,旗下產品ASC40已經獲國家藥監局批准,開展治療中、重度痤瘡患者的二期臨床試驗該研究計劃入組約180名患者,旨在評估各劑量組治療中、重度尋常性痤瘡患者的安全性和有效性。
歌禮創始人、董事長兼首席執行官吳勁梓表示,此為ASC40在同一個月內獲當局批准開展的第二個臨床試驗,是繼非酒精性脂肪性肝炎和復發性膠質母細胞瘤後第三個適應症,顯示出脂質代謝在多個疾病領域中發揮重要作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.